Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests

Reuters03-13

Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests

Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603130805BIZWIRE_USPR_____20260313_BW848518) on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619194223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619194223","market":"nz","top_or_hot":-1,"title":"Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603130805BIZWIRE_USPR_____20260313_BW848518) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> published the original content used to generate this news brief via Business Wire (Ref. ID: 202603130805BIZWIRE_USPR_____20260313_BW848518) on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL6Mpsrx:1","article_id":"2619194223","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619194223","pubTimestamp":1773403746,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc.","BK4588":"碎股","BK4551":"寇图资本持仓","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Guardant Health调查显示92%的人支持结直肠癌血液检测免共付额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9},"content_text":"Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests\n    \n\n        Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603130805BIZWIRE_USPR_____20260313_BW848518) on March 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619194223","isCrawlerRequest":true}